SG10202011388UA - Use of mi r-198 in treating and diagnosing cutaneous squamous cell carcinoma - Google Patents
Use of mi r-198 in treating and diagnosing cutaneous squamous cell carcinomaInfo
- Publication number
- SG10202011388UA SG10202011388UA SG10202011388UA SG10202011388UA SG10202011388UA SG 10202011388U A SG10202011388U A SG 10202011388UA SG 10202011388U A SG10202011388U A SG 10202011388UA SG 10202011388U A SG10202011388U A SG 10202011388UA SG 10202011388U A SG10202011388U A SG 10202011388UA
- Authority
- SG
- Singapore
- Prior art keywords
- treating
- cell carcinoma
- squamous cell
- cutaneous squamous
- diagnosing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/122—Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG10201604845W | 2016-06-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10202011388UA true SG10202011388UA (en) | 2020-12-30 |
Family
ID=60664532
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202011388UA SG10202011388UA (en) | 2016-06-14 | 2017-06-14 | Use of mi r-198 in treating and diagnosing cutaneous squamous cell carcinoma |
SG11201810670VA SG11201810670VA (en) | 2016-06-14 | 2017-06-14 | Use of mi r-198 in treating and diagnosing cutaneous squamous cell carcinoma |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201810670VA SG11201810670VA (en) | 2016-06-14 | 2017-06-14 | Use of mi r-198 in treating and diagnosing cutaneous squamous cell carcinoma |
Country Status (5)
Country | Link |
---|---|
US (1) | US11053496B2 (fr) |
EP (1) | EP3468565A4 (fr) |
CN (1) | CN109789156B (fr) |
SG (2) | SG10202011388UA (fr) |
WO (1) | WO2017217935A1 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110736840A (zh) * | 2019-10-21 | 2020-01-31 | 浙江大学 | Mmp7、ctse或lamc2蛋白在制备肝内胆管细胞癌诊断试剂中的应用 |
US11976331B2 (en) | 2020-01-31 | 2024-05-07 | Castle Biosciences, Inc. | Methods of diagnosing and treating patients with cutaneous squamous cell carcinoma |
US11976333B2 (en) | 2020-01-31 | 2024-05-07 | Castle Biosciences, Inc. | Methods of diagnosing and treating patients with cutaneous squamous cell carcinoma |
CN111793605A (zh) * | 2020-07-31 | 2020-10-20 | 北京中卫医正肿瘤医学研究有限公司 | 一种皮肤鳞癌原代肿瘤细胞的分离提取方法 |
WO2022036245A1 (fr) * | 2020-08-14 | 2022-02-17 | Castle Biosciences, Inc. | Procédés de diagnostic et méthodes de traitement de patients atteints d'un carcinome à cellules squameuses cutané |
CN113235188B (zh) * | 2021-05-10 | 2022-09-06 | 中国科学技术大学 | 一种检测miRNA-198的荧光壳聚糖纤维及其制备方法 |
CN114015775A (zh) * | 2021-11-10 | 2022-02-08 | 张波 | 头颈鳞癌治疗分子探针及应用 |
WO2023225618A2 (fr) * | 2022-05-18 | 2023-11-23 | Yale University | Méthode d'estimation d'un programme moléculaire dynamique d'une cellule |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5451077B2 (ja) | 2006-01-05 | 2014-03-26 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | 肺癌の診断、予後診断及び治療のためのマイクロrnaを基盤とした方法及び組成物 |
US20100310583A1 (en) * | 2007-01-31 | 2010-12-09 | Immune Disease Institute | Let-7 microrna and mimetics thereof as therapeutics for cancer |
US20090326053A1 (en) * | 2008-05-30 | 2009-12-31 | Trustees Of Boston University | Diagnostic uses of follistatin-like 1 |
KR101192297B1 (ko) | 2008-12-10 | 2012-10-17 | 한국생명공학연구원 | 간암에 대한 신규 바이오마커 및 그의 용도 |
WO2010093379A1 (fr) | 2009-02-13 | 2010-08-19 | Fred Hutchinson Cancer Research Center | L'établissement de profils d'expression génétique permet d'identifier des gènes prédictifs d'un carcinome malpighien de la cavité buccale et son pronostic |
CN102892898B (zh) | 2009-12-24 | 2016-03-09 | 复旦大学 | 用于肝细胞癌诊断的含微rna生物标记的诊断试剂盒和方法 |
EP2524059A4 (fr) | 2010-01-13 | 2013-11-20 | Caris Life Sciences Luxembourg Holdings | Détection d'affections gastro-intestinales |
US8987224B2 (en) | 2011-08-05 | 2015-03-24 | Baylor College Of Medicine | MicroRNA-198 as a tumor suppressor in pancreatic cancer |
SG11201500615WA (en) * | 2012-07-27 | 2015-04-29 | Agency Science Tech & Res | Method of promoting wound healing |
CN103173450B (zh) * | 2013-03-07 | 2015-02-18 | 新乡医学院第一附属医院 | 与食管癌术后早期复发及预后相关的miRNA标志物及其应用 |
CN105586390B (zh) * | 2014-10-23 | 2019-01-22 | 王辉云 | 一种用于乳腺癌预后判断的试剂盒 |
-
2017
- 2017-06-14 SG SG10202011388UA patent/SG10202011388UA/en unknown
- 2017-06-14 US US16/310,395 patent/US11053496B2/en active Active
- 2017-06-14 SG SG11201810670VA patent/SG11201810670VA/en unknown
- 2017-06-14 WO PCT/SG2017/050302 patent/WO2017217935A1/fr unknown
- 2017-06-14 CN CN201780049544.9A patent/CN109789156B/zh active Active
- 2017-06-14 EP EP17813708.9A patent/EP3468565A4/fr active Pending
Also Published As
Publication number | Publication date |
---|---|
CN109789156A (zh) | 2019-05-21 |
US11053496B2 (en) | 2021-07-06 |
US20190330625A1 (en) | 2019-10-31 |
EP3468565A4 (fr) | 2020-08-19 |
WO2017217935A1 (fr) | 2017-12-21 |
CN109789156B (zh) | 2022-06-07 |
SG11201810670VA (en) | 2018-12-28 |
EP3468565A1 (fr) | 2019-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10202011388UA (en) | Use of mi r-198 in treating and diagnosing cutaneous squamous cell carcinoma | |
ZA201904695B (en) | Amino-triazolopyridine compounds and their use in treating cancer | |
IL258725A (en) | Polypeptides with an extracellular cd80 site and their use in cancer therapy | |
AU367778S (en) | Cover | |
GB201406473D0 (en) | The use of phytocannabinoids in the treatment of ovarian and skin carcinoma | |
GB2525716B (en) | Electrochemical system with real time modification of composition and use of complex wave form in same | |
ZA201904966B (en) | Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer | |
PL3250116T3 (pl) | Kontaktowa struktura termooptyczna i jej zastosowanie do wykrywania reakcji alergicznych | |
ZA201704726B (en) | Peptides and their use in the treatment of skin | |
IL282836A (en) | 5-halouracil - modified micro RNAs and their use in cancer treatment | |
ZA201904967B (en) | Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer | |
GB201514021D0 (en) | Novel Pyridines and their use in the treatment of cancer | |
IL272414A (en) | Use of gaboksadol in the treatment of diabetes and related conditions | |
EP3788167C0 (fr) | Procédés de diagnostic et de traitement de patients atteints d'un carcinome épidermoïde cutané | |
IL253582B (en) | Detection and treatment of malignant tumors in the central nervous system | |
IL261648A (en) | Cinnolin-4-amine compounds and their use in treating cancer | |
GB201514015D0 (en) | Novel pyridazinones and their use in the treatment of cancer | |
GB2546965B (en) | Improvements in and relating to the treatment of arthrofibrosis | |
IL262076A (en) | Treatment of renal cell carcinoma with lenvatinib and everolimus | |
EP3544622A4 (fr) | Peptidomimétiques et leur utilisation thérapeutique | |
SG11201802955VA (en) | Peptides of use in the preventive and curative treatment of alopecia | |
GB201714668D0 (en) | Improvements in or relating to heating devices and methods | |
AU364557S (en) | Palm vein biometric identification device | |
GB201604714D0 (en) | Methods and devices used in roofing | |
GB201511158D0 (en) | Cell modification and application in therapy |